C27 inhibitor showed encouraging success at the preclinical level to effectively inhibit IL-2 production in a mouse model of staphylococcal enterotoxin B-induced IL-2 release (SEB IL-2 model) (95), which makes it a potent and specific PKC-θ inhibitor candidate for therapy in autoimmune diseases. Here, IL2 is linked to autoimmune disease.